# V5.2 Frozen-Candidate Forward Monitoring Report

## Decision

As of 2026-08-19, the first forward continuation test cannot start. Daily, fund-flow and chip sources have **zero** new common sessions after the 2026-08-16 freeze date, below the pre-registered 25-session checkpoint. The formal status is `WAITING_FOR_DATA`.

This run read coverage metadata only. It did not tune on the already revealed 2026-01-01 through 2026-08-16 window, created zero performance Trials, and left the cumulative Trial count at **1,218**.

## Frozen objects

- raw equal-rank chip/flow ensemble;
- style-residual equal-rank chip/flow ensemble;
- standalone `flow_price_divergence_20_20d`;
- CNY 3m, top 50 buys, 20-session horizon and 10-rank rebalance buffer;
- standard, doubled and conservative cost models;
- immutable 25/60/120 new-common-session checkpoints.

The protocol SHA-256 is `2e6c6128356abde145f8c1655bed6efb88b03c1250119c27e81bcefd02f16138`. A change to window, direction, weight, horizon, universe, buffer or threshold must be a new research program and Trial, not a rewrite of this protocol.

## Coverage check

| Source | Latest partition | New common sessions | Inventory SHA-256 |
|---|---|---:|---|
| Daily | 2026-08-14 | 0 | `240d7320...8cf3` |
| Fund flow | 2026-08-14 | 0 | `140b619a...65e1` |
| Chip | 2026-08-14 | 0 | `afb0f33f...1144` |

## Audit interpretation

This is neither a candidate failure nor a pass; there is no new testable evidence. Repeated early looks at short windows would create hidden multiplicity. At the first checkpoint, the append-only Alpha Court must carry all 1,218 prior Trials, empirical skewness and kurtosis, placebos, purged CPCV/PBO, and standard and doubled costs. The DSR 0.95, PBO 0.05, placebo 0.05 and path thresholds cannot be relaxed.

## Next action

Keep the candidate and protocol frozen. Run the continuation test once 25 genuinely new common sessions exist. Until then, do not publish performance, select replacement parameters or treat historical evidence as live-trading authorization.
